The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Xultophy



Novo Nordisk A/SEU/1/14/947/001-004

Main Information

Trade NameXultophy
Active SubstancesInsulin degludec
Liraglutide
Dosage FormSolution for injection
Licence HolderNovo Nordisk A/S
Licence NumberEU/1/14/947/001-004

Group Information

ATC CodeA10 DRUGS USED IN DIABETES

Status

License statusAuthorised
Licence Issued18/09/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

« Back